H.R. 4408 · 118th Congress (2023–2025)
Promising Pathway Act
This bill provides for expedited, provisional approval of drugs for serious or life-threatening diseases or conditions.
Specifically, the bill allows for provisional approval of drugs that are used to treat, prevent, or diagnose a serious or life-threatening disease or condition for which premature death is likely without early medical intervention. The Food and Drug Administration (FDA) must evaluate applications within 90 days of receipt. The FDA may approve applications if there is early evidence, including real-world and real-time evidence, of the drug's efficacy, as well as substantial evidence of the drug's safety. Provisional approval is valid for two years and may be renewed for up to eight years. The FDA may withdraw provisional approval in the event of serious adverse health effects.
Drug sponsors that receive provisional approval must require all patients receiving the drug to participate in an observational registry, through which the drug sponsor may collect and submit data relating to the drug until it is fully approved. Registries may be operated by the drug sponsor or another entity. The FDA must annually review these registries; sponsors of registries that fail to meet the bill's requirements are subject to civil penalties.
Show official title
To amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 4408’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Mike Gallagher (R-WI-8)
- Cosponsors
10 cosponsors
4 original · 6 later
5 R · 5 D
- Rep. Brian K. Fitzpatrick (R-PA-1)· Original · Jun 30, 2023
- Rep. Mike Quigley (D-IL-5)· Original · Jun 30, 2023
- Rep. Eric Swalwell (D-CA-14)· Original · Jun 30, 2023
- Rep. Bruce Westerman (R-AR-4)· Original · Jun 30, 2023
- Rep. Anthony D'Esposito (R-NY-4)· Later · Aug 8, 2023
- Rep. Dean Phillips (D-MN-3)· Later · Oct 26, 2023
- Rep. Lois Frankel (D-FL-22)· Later · Dec 7, 2023
- Rep. Josh Gottheimer (D-NJ-5)· Later · Dec 7, 2023
- Rep. Joe Wilson (R-SC-2)· Later · Dec 7, 2023
- Rep. Mike Garcia (R-CA-27)· Later · Apr 5, 2024
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Civil actions and liability
- Congressional oversight
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Health information and medical records
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Jun 30, 2023 – Jul 7, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Promising Pathway Act
Display title, Short title · Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.
Official title · Introduced in House